tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Finn L et al. | Epstein-Barr virus infections in children after transplantation of the small intestine. | 1998 | Am. J. Surg. Pathol. | pmid:9500771 |
| Randhawa PS et al. | The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. | 1993 | Am. J. Surg. Pathol. | pmid:7680544 |
| Minervini MI et al. | Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). | 2000 | Am. J. Surg. Pathol. | pmid:10757402 |
| Randhawa PS et al. | Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. | 1996 | Am. J. Surg. Pathol. | pmid:8772784 |
| Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
| Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
| Levitsky J and Feng S | Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. | 2014 | Am. J. Transplant. | pmid:24620373 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Cavadas PC et al. | Bilateral trans-humeral arm transplantation: result at 2 years. | 2011 | Am. J. Transplant. | pmid:21521475 |
| Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
| Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
| Asrani SK et al. | De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. | 2014 | Am. J. Transplant. | pmid:24456026 |
| Song L et al. | ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. | 2017 | Am. J. Transplant. | pmid:27598231 |
| Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
| Egli A et al. | Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. | 2010 | Am. J. Transplant. | pmid:20840474 |
| Touzot M et al. | Renal transplantation in HIV-infected patients: the Paris experience. | 2010 | Am. J. Transplant. | pmid:20840478 |
| Saikali JA et al. | Sirolimus may promote thrombotic microangiopathy. | 2003 | Am. J. Transplant. | pmid:12603218 |
| Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
| McKenna G and Trotter JF | Does early (CNI) conversion lead to eternal (renal) salvation? | 2010 | Am. J. Transplant. | pmid:20928938 |
| Hanto DW et al. | Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. | 2010 | Am. J. Transplant. | pmid:20977633 |
| Al-Massarani G et al. | Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. | 2008 | Am. J. Transplant. | pmid:18925903 |
| Frassetto LA and Benet LZ | Pharmacogenomics and transplantation: where are we? | 2004 | Am. J. Transplant. | pmid:15147415 |
| MacPhee IA et al. | The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15147425 |
| Hirsch HH et al. | Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. | 2013 | Am. J. Transplant. | pmid:23137180 |
| Alloway RR et al. | A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. | 2012 | Am. J. Transplant. | pmid:22759200 |
| Hesselink DA et al. | Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | 2005 | Am. J. Transplant. | pmid:15816878 |
| Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
| Muthusamy AS et al. | Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. | 2008 | Am. J. Transplant. | pmid:18828772 |
| Srinivas TR et al. | The noninferiority trial: don't don't do it. | 2010 | Am. J. Transplant. | pmid:21087412 |
| Madariaga ML et al. | Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. | 2015 | Am. J. Transplant. | pmid:25824550 |
| Vanrenterghem Y et al. | Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. | 2005 | Am. J. Transplant. | pmid:15636615 |
| Sindhi R et al. | Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. | 2005 | Am. J. Transplant. | pmid:15636616 |
| Shergill AK et al. | Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. | 2005 | Am. J. Transplant. | pmid:15636619 |
| Cendales L et al. | Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. | 2015 | Am. J. Transplant. | pmid:25773260 |
| Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
| Pondrom S | The AJT report. | 2008 | Am. J. Transplant. | pmid:18324976 |
| Guirado L et al. | Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21668633 |
| Flechner SM et al. | The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. | 2011 | Am. J. Transplant. | pmid:21668635 |
| Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
| Servais A et al. | Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. | 2011 | Am. J. Transplant. | pmid:21672152 |
| Maes BD et al. | Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. | 2002 | Am. J. Transplant. | pmid:12484345 |
| Asberg A et al. | Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. | 2010 | Am. J. Transplant. | pmid:20486914 |
| Ryan CM and Swanson DP | clinical research, innovative practice and IRB review: identifying and respecting boundaries. | 2007 | Am. J. Transplant. | pmid:17331113 |
| Hautz T et al. | Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. | 2010 | Am. J. Transplant. | pmid:20353468 |
| Pallet N et al. | Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. | 2015 | Am. J. Transplant. | pmid:25588704 |
| Min SI et al. | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. | 2013 | Am. J. Transplant. | pmid:23734831 |
| Lefaucheur C et al. | Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. | 2008 | Am. J. Transplant. | pmid:18671673 |
| Haufroid V et al. | CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. | 2006 | Am. J. Transplant. | pmid:17049058 |
| Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
| Mandelbrot DA et al. | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. | 2015 | Am. J. Transplant. | pmid:26176342 |